

www.elsevier.com/locate/redox

MITOCHONDRIAL DYSFUNCTION IN PARKINSONIAN MESENCHYMAL STEM CELLS IMPAIRS DIFFERENTIATION

Plamena R. Angelova, Mario Barilani, Chris Lovejoy, Marta Dossena, Mariele Viganò, Agostino Seresini, Daniela Piga, Sonia Gandhi, Gianni Pezzoli, Andrey Y. Abramov, Lorenza Lazzari

PII: S2213-2317(17)30743-7
DOI: https://doi.org/10.1016/j.redox.2017.10.016
Reference: REDOX781

To appear in: *Redox Biology*

Received date: 29 September 2017
Revised date: 18 October 2017
Accepted date: 20 October 2017

Cite this article as: Plamena R. Angelova, Mario Barilani, Chris Lovejoy, Marta Dossena, Mariele Viganò, Agostino Seresini, Daniela Piga, Sonia Gandhi, Gianni Pezzoli, Andrey Y. Abramov and Lorenza Lazzari, MITOCHONDRIAL DYSFUNCTION IN PARKINSONIAN MESENCHYMAL STEM CELLS IMPAIRS DIFFERENTIATION, *Redox Biology,* https://doi.org/10.1016/j.redox.2017.10.016

MITOCHONDRIAL DYSFUNCTION IN PARKINSONIAN MESENCHYMAL STEM CELLS IMPAIRS DIFFERENTIATION

Plamena R. Angelova[11], Mario Barilani[2,3,1], Chris Lovejoy[1], Marta Dossena[2], Mariele Viganò[2], Agostino Seresini[4,5], Daniela Piga[6,7], Sonia Gandhi[1], Gianni Pezzoli[4], Andrey Y. Abramov[1,*], Lorenza Lazzari[2]

[1]Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK

[2]Unit of Regenerative Medicine – Cell Factory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

[3]EPIGET LAB, Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy

[4]Fondazione Grigioni per il Morbo di Parkinson, Milano, Italy

[5]Medical Genetics Laboratory, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

[6]Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT)

[7]University of Milan, Neurology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

*Corresponding author. Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK; Tel.: +442034484062.

a.abramov@ucl.ac.uk

Abstract

Sporadic cases account for 90-95% of all patients with Parkinson's Disease (PD). Atypical Parkinsonism comprises approximately 20% of all patients with parkinsonism. Progressive Supranuclear Palsy (PSP) belongs to the atypical parkinsonian diseases and is histopathologically classified as a tauopathy. Here, we report that mesenchymal stem cells (MSCs) derived from the bone marrow of

[1] These authors equally contributed to this work